Protective effects of ginsenoside Rb1 on septic rats and its mechanism.
This study aims to observe the protective effects of ginsenoside Rb1 on liver and lung in rats with septic shock and reveal its mechanism. Rats were randomly divided into three groups: sham, cecal ligation and puncture (CLP), and CLP with ginsenoside Rb1. Then, the survival rate, arterial blood pressure, TLR4 mRNA, and TNF-α levels were determined. The liver and lung tissues were stained with hematoxylin-eosin (HE). The overall survival rate of the Rb1 group was significantly higher than that of the CLP group. Mean arterial blood pressure went down in both the CLP and Rb1 groups after CLP, and there was a significant difference both in the sham and Rb1 groups when compared with the CLP group. The Rb1 treatment group had markedly lower TLR4 mRNA expression and TNF-α levels than the CLP group. In the CLP group, pathology showed swelling, degeneration, necrosis, and neutrophil infiltration in the liver and alveolar epithelial cells. However, in the Rb1 group, there was mild degeneration and slight neutrophil infiltration, but no obvious necrosis. Rb1 may improve the survival rate, ameliorate arterial blood pressure, and protect the liver and lung in septic shock rats by downregulating the expression of TLR4 mRNA and inhibiting the production of TNF-α.
Department of Emergency and ICU, Fourth Affiliated Hospital of Nanchang University, Nanchang 330003, Jiangxi, China.
Li Li
LL
Wu
Department of Emergency and ICU, Fourth Affiliated Hospital of Nanchang University, Nanchang 330003, Jiangxi, China.
Bao Hui
BH
Jia
Department of Emergency and ICU, Fourth Affiliated Hospital of Nanchang University, Nanchang 330003, Jiangxi, China.
Jian
J
Sun
Department of Emergency and ICU, Fourth Affiliated Hospital of Nanchang University, Nanchang 330003, Jiangxi, China.
Jun Xi
JX
Chen
Department of Emergency and ICU, Fourth Affiliated Hospital of Nanchang University, Nanchang 330003, Jiangxi, China.
Zhong Ying
ZY
Liu
School of Life Sciences and Food Engineering, Nanchang University, Nanchang 330031, Jiangxi, China.
Yuan
Y
Liu
D000818:Animals; D004353:Drug Evaluation, Preclinical; D036145:Ginsenosides / Q000494:pharmacology / Q000627:therapeutic use*; D048550:Hepatic Insufficiency / Q000209:etiology / Q000517:prevention & control*; D055370:Lung Injury / Q000209:etiology / Q000517:prevention & control*; D009206:Myocardium / Q000378:metabolism; D005894:Panax; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D018805:Sepsis / Q000150:complications / Q000188:drug therapy*; D051197:Toll-Like Receptor 4 / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D036145:Ginsenosides; D010936:Plant Extracts; C495347:Tlr4 protein, rat; D051197:Toll-Like Receptor 4; D014409:Tumor Necrosis Factor-alpha; C442759:ginsenoside Rb1